|Dr. Ragupathy Madiyalakan||CEO & Director||40k||N/A||N/A|
|Mr. Pierre Vermette||Chief Financial Officer||70k||N/A||N/A|
|Mr. Roger Andrews||Head of Investor Relations & Corp. Communications||N/A||N/A||N/A|
|Mr. Douglas C. Bachman||VP of Corp. Devel.||N/A||N/A||1954|
|Mr. Thomas Woo||VP of Product Devel.||N/A||N/A||N/A|
Quest PharmaTech Inc., a biopharmaceutical company, develops and commercializes antibody based immunotherapeutic products for cancer. Its lead product candidates are Mab AR 9.6 against truncated O-glycan on MUC16 for targeted cancer therapy applications; and Oregovomab, an anti-CA-125 antibody, which has completed Phase II clinical trial for the treatment of ovarian cancer. The company also develops combinatorial immunotherapeutic products for cancer by using monoclonal antibodies of the immunoglobulin G and E class in combination with chemotherapy/immune-adjuvant; and immunotherapy products for pancreatic cancer. In addition, it develops products by using proprietary transdermal delivery technologies for dermatology and wound healing applications; and skin penetrating active molecules for cosmetic and pharmaceutical use. Quest PharmaTech Inc. is headquartered in Edmonton, Canada.
Quest PharmaTech Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.